SCHEMBL3336447

SCHEMBL3336447

Nc1nc(OCCF)c2cc(Br)ccc2n1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1B1 Q16678 2/20 0.50
ADORA2A P29274 1/20 0.43
HTT P42858 1/20 0.41
PABPC1 P11940 1/20 0.41
DHFR P00374 1/20 0.37
SLC6A2 P23975 1/20 0.37
SLC6A4 P31645 1/20 0.37
BCHE P06276 4/20 0.37
ACHE P22303 4/20 0.37
GRIN1 Q05586 4/20 0.37
GRIN2A Q12879 4/20 0.37
MAPT P10636 2/20 0.37
LMNA P02545 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
RXFP1 Q9HBX9 1/20 0.37
NT5E P21589 1/20 0.36
ADRB2 P07550 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3338894 0.89 L3MBTL1 (0.43) CYP1B1ADORA2AHTTPABPC1MAPT
SCHEMBL3333609 0.84 ALDH1A1 (0.43) ADORA2AHTTPABPC1DHFRCYP1A2
SCHEMBL3337990 0.82 DHFR (0.49) ADORA2AHTTPABPC1DHFRBCHE
SCHEMBL3337725 0.82 NT5E (0.44) ADORA2AHTTPABPC1DHFRBCHE
SCHEMBL3335114 0.81 TOP2A (0.46) ADORA2AHTTSLC6A4MAPTLMNA
SCHEMBL3335633 0.79 MGMT (0.50) ADORA2AHTTMAPTLMNACYP1A2
SCHEMBL3331276 0.79 CYP1B1 (0.41) CYP1B1ADORA2ADHFRMAPT
SCHEMBL3335972 0.78 KDM4E (0.39) CYP1B1ADORA2AHTTLMNAADRB2
SCHEMBL3333468 0.78 CDK2 (0.44) ADORA2AHTTPABPC1DHFRBCHE
SCHEMBL22234061 0.77 HRH4 (0.42) CYP1B1ADORA2APABPC1DHFRACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8673929-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections GILEAD SCIENCES, INC. (US) 2014-03-18 US disclosed
US-20100143299-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2010-06-10 US disclosed
WO-2008009077-A2 4,6-DL- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2008-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100143299-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS OPRD1, IFNAR1, NR4A1 CYP1B1 635/4885ADORA2A 1968/4885HTT 3738/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.